Drug intelligence / Profile preview

RHB-204

Development stage: Unknown
Lead developer: RedHill Biopharma
Modality: Small Molecules
Administration: Oral

Overview

RHB-204 is an investigational, oral, fixed-dose combination therapy consisting of clarithromycin, rifabutin, and clofazimine. Developed by RedHill Biopharma, it is specifically designed for the treatment of pulmonary Mycobacterium avium complex (MAC) disease in adults with nodular bronchiectasis. The combination leverages the distinct mechanisms of its three antibiotic components to provide a potent and simplified treatment regimen. RHB-204 is currently in Phase 3 clinical development (CleaR-MAC trial) and has been granted Orphan Drug and Qualified Infectious Disease Product (QIDP) designations by the FDA, which provide for extended market exclusivity and eligibility for fast-track status.

Targets

Bacterial 50S ribosomal subunitNeuraminidaserpoB (DNA-directed RNA polymerase subunit beta)

Beyond the preview

Go deeper on RHB-204.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RHB-204.

Explore the full profile